Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
after all the 182,989 posts about xkem( yes 182,989 posts) we still sit at .0005 and about to fade to zero.. what a waste of time and a joke.. good luck with your other investments people..
XECHEM INTERNATIONAL NEEDS UP TO ADDED $1M TO CONTINUE OPS '08
*XECHEM INTERNATIONAL SAYS DIFFICULTY RAISING CAPITAL FOR OPS
XECHEM ON TAPE.. NOT GOOD NEWS..XECHEM INTERNATIONAL REMAINS IN DEFAULT FOR TOTAL $14M
you must lead a truely lonely and unfulfilled life.. i feel for people like you.. so sad!
stop the bs.. so full of it! just stop!
i was talking about the last pics from late 2007..and im not a pumper.. have owned this pos for 5 yrs now pal!!
imo something is cookin and it won't be more than 2 weeks before we find out!! if those factory pic's are not fakes then the news will be to the upside...bigtime!
from my reuters screen shows 2 lots of 5 million canceled at 1:16pm est and 1:17pm est .002
43 ... june 1st coming.. keep praying lochute
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 8, 2008
XECHEM INTERNATIONAL, INC.
-----------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-23788 22-3284403
----------- --------- ----------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
379 Thornall, Edison, NJ 08818
------------------------------
(Address of principal executive offices and Zip Code)
Registrant's telephone number, including area code (732) 205-0500
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
<PAGE>
Section 4 - Matters Related to Accountants and Financial Statements
Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related
Audit Report or Completed Interim Review
The Company determined that, as of December 03, 2007, its financial statements
for December 31, 2002 through March 31, 2007 may be inaccurate due to unrecorded
financial issues related to Xechem (India) Pvt.; Ltd. ("Xechem India"), which it
has historically reported as a 2/3 owned subsidiary, engaged to assist the
Company in its drug development efforts, among other things. The Company has
been unable to locate any documentation establishing the 2/3 ownership of the
subsidiary, as previously certified by its former CEO, Dr. Ramesh Pandey.
Therefore, these financial statements should not be relied upon. It should be
noted that the Company has not engaged in any active operations of the
subsidiary since Dr. Pandey's departure as CEO. In addition, the Company has
instituted suit in India against Dr. Pandey and others named as shareholders in
the last public filing made by Xechem India seeking among other things, a
declaration as to ownership of Xechem India, an accounting of its expenditures,
right to review books and records and appropriate relief should expenditures
have not been made for the benefit of the Company. The court has provided that
the Company has a right to see the books and records of Xechem India and the
Company intends to continue the litigation until further determinations can be
made.
The financial statements may require restatement if it is determined that the
Company did not own any of Xechem India. The Company has advised its independent
accountants of this development.
The Board of Directors concluded that the previously issued financial statements
should not be relied upon because the Company is in litigation in India with
former CEO, Dr. Pandey, over the ownership of an Indian company to whom the
Company had loaned money in the range of $900,000 to $1,000,000, more or less.
This series of transactions may not have been properly accounted for in prior
years financials and may have been related party transactions or possibly should
have been treated as minority ownership of a subsidiary. Full accounting on
these issues has not yet been completed due to the delays inherent in
litigation.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: February 8, 2008
XECHEM INTERNATIONAL, INC.
By: /s/ Robert Swift
-----------------------------------
Robert Swift, Chief Oversight Officer
can't read the file.. whats the bottom line? thxs
.13cents..... next 4 months.. or..... zero!
how much? and who paid last time? and how do u pay? money order?
Im willing to bet Barbara knows ALOT more than she says. And here is an extremely important question: Why can't we get new pictures of the factory from the same person that took them in november?? Who here on the board was responsible for getting those pics's to the i-box?
bottom line here folks: 3 outcomes.... 1) swift f'd us and will take xkem private..( don't think so) 2) pandey f'd us and burn't thru all the $$$ ( don't think ALL) 3) things got f'ed up w/ pandey but swift and crew had huge investment in co. and are sorting thru the countless problems and will make this work. probably the likely outcome.. but will take some time.. at this point we only have FAITH!!! Right Lochute??
Sickle Cell Patients in More Pain Than Previously Thought
By Rose Hoban
18 January 2008
Hoban Report - Download MP3 (589 k)
Listen to Hoban Report
Sickle cell anemia is a reality for millions of people with roots in Africa, the Mediterranean basin, the Middle East and parts of India. It's a genetic disease of the blood. Red blood cells, which usually look like donuts, deform into the shape of a crescent, or sickle blade shape, thus the name. This severely impedes their ability to carry oxygen throughout the body, and can result in debilitating pain for patients. As Rose Hoban reports, doctors are just now learning how painful the disease can be.
A normal blood cell carries oxygen throughout the body
Dr. Wally Smith from the Virginia Commonwealth University says most doctors believe that the 'pain crises' associated with sickle cell disease are occasional events. But in his practice, he was seeing patients who reported pain more frequently.
"Patients felt like they were getting a lot of pain at home," Smith says. "Their quality of life was poor, and they were not able to work, go to school, have children, get married and do the things that you would expect a patient who's mostly healthy to do."
So, Smith decided to study how often these patients actually experienced pain. He gave several hundred people diaries to record daily how much pain they were having. He says he was surprised by what the subjects reported.
Sickle-shaped cells clump together and block blood flow in blood vessels, causing pain
"More than a quarter, almost of third of the patients experienced sickle cell pain nearly daily, 95 out of every 100 days," he says. "And that was completely different than what the textbooks had said, or what researchers have generally perceived in the past."
"We also found that in general, this pain was much more frequent and severe than what was previously reported. About a good half of the patients said they had pain more than half of the time."
Often, Smith says, sickle cell patients are perceived as manipulative or as complainers when they come to a hospital or doctor's office looking for opiate medication to treat sickle cell pain. But his study shows that the patients were only asking for drugs when the pain became unbearable. "They managed their pain at home, that was the other big surprise," Smith reports. "So no matter how bad the pain was, most of the time they stayed at home, even if they thought they were in a crisis."
Smith says his findings are particularly disturbing in light of the fact that many countries in Africa and Asia, where there are many sickle cell sufferers, lack ready access to pain medicine. Smith recounts a story of a visiting government official from an African country who asked him to write a prescription for his son, because he was unable to obtain opiate medications in his own country.
His study is published in Annals of Internal Medicine.
Sickle Cell Patients in More Pain Than Previously Thought
By Rose Hoban
18 January 2008
Hoban Report - Download MP3 (589 k)
Listen to Hoban Report
Sickle cell anemia is a reality for millions of people with roots in Africa, the Mediterranean basin, the Middle East and parts of India. It's a genetic disease of the blood. Red blood cells, which usually look like donuts, deform into the shape of a crescent, or sickle blade shape, thus the name. This severely impedes their ability to carry oxygen throughout the body, and can result in debilitating pain for patients. As Rose Hoban reports, doctors are just now learning how painful the disease can be.
A normal blood cell carries oxygen throughout the body
Dr. Wally Smith from the Virginia Commonwealth University says most doctors believe that the 'pain crises' associated with sickle cell disease are occasional events. But in his practice, he was seeing patients who reported pain more frequently.
"Patients felt like they were getting a lot of pain at home," Smith says. "Their quality of life was poor, and they were not able to work, go to school, have children, get married and do the things that you would expect a patient who's mostly healthy to do."
So, Smith decided to study how often these patients actually experienced pain. He gave several hundred people diaries to record daily how much pain they were having. He says he was surprised by what the subjects reported.
Sickle-shaped cells clump together and block blood flow in blood vessels, causing pain
"More than a quarter, almost of third of the patients experienced sickle cell pain nearly daily, 95 out of every 100 days," he says. "And that was completely different than what the textbooks had said, or what researchers have generally perceived in the past."
"We also found that in general, this pain was much more frequent and severe than what was previously reported. About a good half of the patients said they had pain more than half of the time."
Often, Smith says, sickle cell patients are perceived as manipulative or as complainers when they come to a hospital or doctor's office looking for opiate medication to treat sickle cell pain. But his study shows that the patients were only asking for drugs when the pain became unbearable. "They managed their pain at home, that was the other big surprise," Smith reports. "So no matter how bad the pain was, most of the time they stayed at home, even if they thought they were in a crisis."
Smith says his findings are particularly disturbing in light of the fact that many countries in Africa and Asia, where there are many sickle cell sufferers, lack ready access to pain medicine. Smith recounts a story of a visiting government official from an African country who asked him to write a prescription for his son, because he was unable to obtain opiate medications in his own country.
His study is published in Annals of Internal Medicine.
E-mail This Article
Print Version
Top Story
At Least 9 Killed in Latest Kenyan Election Protests
Related Links
more about sickle cell
FAQs | Terms of Use & Privacy Notice | Broadcasting Board of Governors | Site Map | Link to Us
| Contact Us
he completely plays both sides of the fence.. fake.
GO GET EM' CHUTEMAN!!!
You are correct .. you dont .. but thxs for the number.
BACK THAT STATEMENT UP.. WHO DID YOU SPEAK WITH AND WHAT IS THEIR PHONE NUMBER????
IT'S good to see true longs feeling better about their investment ( xkem ).... i know i am.. it has taken some time but im thinking maybe..just maybe.. we might pull this off..!! lol
Largest volume day since july 18th! nice...
**** NOT SURE IF ALREADY POSTED.. but nicosan mentioned here.. toward the end of the article.. ***Africa Warms Up to Biotechnology"
Op-Ed, Business Daily, (Nairobi)
November 15, 2007
Authors: Ismail Serageldin, Calestous Juma, Professor of the Practice of International Development; Director, Science, Technology, and Globalization Project
Belfer Center Programs or Projects: Science, Technology, and Globalization; Science, Technology, and Public Policy
Much of the debate about biotechnology in Africa assumes that African countries are only being asked to accept products developed elsewhere. To the contrary, Freedom to Innovate: Biotechnology in Africa’s Development shows that extensive biotechnology research is under way in Africa.
Africa’s governments, its industry and its research institutions are well aware of the potential that agricultural biotechnology holds if applied in other ways and to indigenous crops.
A study of 13 public institutions in Kenya, Zimbabwe, Egypt and South Africa showed that biotechnology applications have been performed on 21 crops.
The genes incorporated into the crops include those that confer insect, fungal, viral and bacterial resistance, protein quality improvements, herbicide tolerance, and salt and drought resistance.
In South Africa, for example, about 20 to 30 per cent of yellow maize and 80 per cent of cotton are now genetically modified varieties.
Estimates for 2004 production showed that about 27 per cent of total yellow maize crop (for animal feed) was genetically-modified (GM).
Less than eight per cent of the white maize grown (for human consumption) is GM.
An insect-resistant potato was developed in South Africa in 2001. The goal was to help small farmers to grow this on a commercial scale. The potatoes performed well in field trials but commercialisation has been delayed.
The first GM biotechnology product to be developed in Kenya was a virus-and weevil-resistant sweet potato. This project began in 1991. The sweet potato trials met some setbacks because it is believed that the construct for the virus resistance was not well tested and it did not perform well under field trials.
In addition, KARI in partnership with the international maize laboratory CYMMIT in Mexico has been developing insect resistant transgenic maize. The maize was tested in field trials in May 2005.
Egypt has worked on more varieties of crops than any other country in Africa. The Genetic Engineering Services Unit (GESU) of the Agricultural Genetic Engineering Research Institute (AGERI) in Egypt has been actively involved in micropropagation of Satavia rebaudiana and mulberry, as well as the production of diagnostic kits for detecting viruses in banana, potato, tomato and beans.
Plant biotechnology research at AGERI also includes transferring genes that confer virus resistance, bacterial resistance, insect resistance, stress tolerance and fungal resistance on such crops as potato, cotton, maize, faba beans, cucurbits, wheat, banana and date palm.
Insect resistant potato is another of the major crops that have been worked on in Egypt by AGERI in partnership with Michigan State University in the USA. Several varieties of potato were transformed for potato tuber moth resistance including a widely grown Dutch variety in Egypt, Spunta. Spunta.
The potato has not been commercialised because of trade concerns in the European Union over GM crops.
The Uganda National Agricultural Research Organisation (NARO) opened a new research laboratory in 2003 to conduct work on the genetic modification of banana. The goal was to insert genes that will confer resistance to Black Sigatoka and banana weevils.
Field trials on Bt cotton have been carried out in several countries including Kenya, Zambia, and Zimbabwe. Tanzania and Burkina Faso have recently started field trials, while Mali was slated to start field trials in 2005. However, a cotton trial in Zambia has had to be halted because biosafety regulations were not ready at the time.
Biotechnology is being employed to improve the nutritional content of sorghum thanks to the work of a consortium of institutions from Africa, Japan and the US.
Funded by the Gates Foundation and led by Kenya-based Africa Harvest, the consortium’s members include the South African Council for Scientific and Industrial Research (CSIR), the African Agricultural Technology Foundation, the Forum for Agricultural Research in Africa (FARA), and the Agricultural Research Council (ARC) of South Africa.
Livestock is critical to agriculture and to food production in Africa, as it is elsewhere.
Yet, according to some estimates, Africa’s livestock community is expected to become the most important agricultural sector in terms of physical products derived from agriculture, such as meat products and leather.
The International Livestock Research Institute (ILRI) is at the forefront of using biotechnology to develop new and improved animal vaccines as well as developing diagnostic tools to combat livestock diseases. These include in particular the high-priority ‘orphan’ diseases of Africa and South Asia.
The centre’s research is also aimed at conserving the wealth of what is called the ‘barnyard’ genetic diversity of Africa and other developing nations; and for improving the feed value of crops in crop-livestock systems.
One third of its US$35 million annual budget is spent on research in biotechnology.
More than 100 scientists, technicians and students work in an array of fields including bioinformatics, biometrics, diagnostics, immunology, microbiology, parasitology, and recombinant DNA technology.
Specific ILRI projects include research to identify genetic markers for tolerance to African trypanosomiasis in N’Dama cattle, and for resistance to parasites in Red Maasai sheep.
ILRI is currently looking to develop a vaccine against East Coast Fever (caused by Theileria parva) in cattle and preliminary trials with five candidate vaccines are currently underway. The Laboratoire National de l’Elevage et de Recherches veterinaires (LNERV) in Senegal is West Africa’s principal veterinary research laboratory.
Established more than 50 years ago, LNERV has extensive experience of research in animal health and husbandry, particularly in developing vaccines. LNERV is also involved in developing diagnostic tools for better surveillance of animal diseases.
LNERV is also involved in developing and implementing disease control strategies in Senegal and broader West Africa.
LNERV has also produced rinderpest and African swine fever diagnostic kits as well as 25 different types of veterinary vaccines equivalent to some 50 million doses per year. New vaccines in the pipeline include those for anthrax, Newcastle disease in rural poultry and Rift Valley fever.
In South Africa, biotechnology is being used to develop molecular diagnostic kits for tick-borne diseases found in livestock.
Where South Africa leads the way is in bringing together and leading consortia of public and private sector groups in developed and developing countries.
One testing kit that was launched in March 2005, for example, was produced through collaborative work carried out by a consortium comprising the University of Pretoria, Utrecht University, Isogen Life Science and the ARC-Onderstepoort Veterinary Institute.
Work is currently underway to transfer genetic material from the indigenous Bosmara cattle to farmers in developing countries using embryo transfer technology.
The aim here is to transfer useful traits in cattle breeds in other countries using conventional animal breeding methods. Several live recombinant vaccines have been developed for use in primates and livestock.
Ethiopia’s National Veterinary Institute (NVI) has the capability to study and screen micro-organisms for biological compounds that could have applications in vaccines and other therapeutic purposes. The institute produces viral vaccines against Rinderpest, Sheep-pox, Newcastle disease, African horse sickness, foot-and-mouth disease.
It also produces bacterial vaccines against contagious Bovine pleuropneumonia, anthrax, and blackleg, among others. NVI developed a recombinant DNA-based vaccine against Rinderpest in collaboration with University of California, Davis.
Vaccine research is also carried out extensively by the University of Ibadan, Nigeria.
The university works on a research project on DNA sequencing of vaccines for the prevention of the infectious Bursal disease (also known as Gumboro disease), a major source of poultry deaths worldwide. There is no known cure for the disease.
Biotechnology in healthcare offers more effective disease diagnosis, prevention and treatment. In the coming years, it is going to change how we understand and treat diseases.
And, as in agriculture, the health biotech sector also offers much potential for boosting Africa’s economies. Health biotechnologies allow scientists to identify genes linked to particular diseases. In addition, new technologies allow researchers to develop genetic tests for a range of illnesses.
Several African countries now have programmes dedicated to healthcare biotechnology R&D. These include Egypt, Kenya, South Africa, Tanzania and Uganda.
For example, the application of molecular markers for mapping disease resistance in the malaria parasite Plasmodium falciparum is being carried out at the Tanzania’s Ifakara Health Research and Development Centre.
Another activity that has Africa-wide implications is the search for natural products, often used in traditional medicines, but which could have potential uses in modern pharmaceutical research.
A good example is that of NICOSAN, a herbal medicine commonly used in Africa. Nigeria’s National Institute for Pharmaceutical Research and Development in Abuja has discovered that it is also effective in treating sickle-cell disorder.
Applications of indigenous knowledge in health biotechnology research and development include isolating and patenting active ingredients from a plant Hoodia gordonii, which has hunger-suppressing properties. This plant has been traditionally used by the San people who live in a semi-desert part of Botswana, to suppress hunger and thirst during long bouts of hunting.
In addition, under the Southern African Biosciences Network (SANBio) the CSIR of South Africa and other collaborations in Southern Africa are engaged in a project to scientifically-validate traditional medicines for their potential to treat infections suffered by people living with HIV/Aids. Kenya has developed an inexpensive but effective diagnostic testing kit for Hepatitis B called Hepcell.
Now in use in all district and provincial hospitals, Hepcell is an indigenous effort led by the Kenya Medical Research Institute (KEMRI) with support from the Japan International Cooperation Agency (JICA).
Egypt also has an active healthcare biotechnology industry. Products have been developed that can treat such conditions as cardiovascular, cancer, anaemia and diabetes.
Africa is claiming its place in the world of biotechnology. The lessons contained in Freedom to Innovate will help policy makers strengthen these efforts, forge greater international partnerships and establish Africa as an emerging player in the biotechnology revolution.
Dr Serageldin is director of the Library of Alexandria and member of the Senate of Egypt, and Prof Juma teaches at Harvard University’s Kennedy School of Government. They co-chair the High-Level African Panel on Biotechnology of the AU and NEPAD.
For more information about this publication please contact the Belfer Center Communications Officer at 617-495-5468.
Full text of this publication is available at:
http://www.bdafrica.com/index.php?option=com_content&task=view&id=4313&Itemid=58
48
For Academic Citation:
Serageldin, Ismail and Calestous Juma. "Africa Warms Up to Biotechnology." Business Daily (Nairobi) (November 15, 2007).
MOST VIEWED PUBLICATIONS MOST VIEWED - OPEDS POLICY BRIEF: AUTO EMISSIONS
No choice -- withdrawal starts in '08
Iraq Progress Report: Reading Between the Lines
Ibrahim Index of African Governance
more publications ›
No choice -- withdrawal starts in '08
The End of Tyranny in Zimbabwe
Extreme Do-Over May Unify Iraq
more publications ›
Policy Options for Reducing Oil
i tried.. they don't take walk in visitors.. farce!
"That is why it is important to figure out if your informant is buying on the open market...If he is, then we will be just fine!" That IMO is the single most important question that needs to be answered.. even with all the months of silence.. if basu & co. are actively( but slowly ) buying on open mkt we are fine.. good point chute-ster.
its all a MYSTERY..MAN!! LOL
yes.. you are 1000% correct!!
wow..... i see after 5 yrs of owning this pos i still haven't made any headway!!!! it's all speculation at best .. only hope at this point is NICOSAN!! We will see.
YES.. SELL NOW.. AND STOP THE WHINING.
What we need here is more COWBELL!!!!
BRAVO Jim!!!! Finally a voice of reason during this period of confusion and chaos. I 1000% agree .. we just have to let this play out.. and STICK to the facts.. not heresay.
if i see new pic's showing good progress i will never curse this company again.. lol.
WE NEED NEW FACTORY PICTURES. At least that would show forward momentum... Who had that contact for the last set of pic's??
im certainly holding at this point.. there isn't much downside left now..
this is a damn shame.. this has become a freakin circus show.. im just holding and hoping for a LOCHUTE miracle! lol
drift.. you say nicosan "not" selling well? and hinch says they are selling tons of it??? which is it? Looks like we are back to square one again.. WE KNOW NOTHING !
virgin mobile voice recording.. no name given.. whats the other number plse?